About this trial
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.
The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using ultrasound and biomarkers.
Eligibility criteria
Qualifiers
oncological patient in the field of gastrointestinal tumors
patients with liver cirrhosis
patients attending the intensive care unit
Disqualifiers
patients incapable of consenting
patients with congenital muscle diseases
Trial design
Treatments tested in this trial
- Ultrasound